Recent Posts
News•Mar 2, 2026
Bioxytran Reports Positive Phase 1b/2a Results for Antiviral ProLectin‑M
Bioxytran announced positive phase 1b/2a data for its oral antiviral ProLectin‑M in a randomized, double‑blind, placebo‑controlled trial of 39 mild‑to‑moderate COVID‑19 patients in India. The highest dose (16,800 mg/day) achieved viral clearance in 90% of participants by day 5 versus 20% on placebo, with faster clinical improvement and no serious adverse events. All dose groups cleared virus by day 7, matching the natural disease course. The results support further development of this galectin‑targeting therapy as a potential first‑line oral treatment.
By PharmaTimes
News•Feb 25, 2026
Verdiva Bio Completes Enrolment for Phase 2b Study of Oral GLP‑1 Candidate VRB‑101
Verdiva Bio announced that enrollment for its phase 2b EVOLVE‑2 trial of VRB‑101, a once‑weekly oral GLP‑1 peptide analog for weight loss, is complete with more than 200 participants across 22 U.S. sites. The double‑blind, placebo‑controlled study will assess safety, tolerability...
By PharmaTimes
News•Feb 17, 2026
Katerina Leftheris
Enhanced Genomics announced the appointment of Katerina Leftheris to its board of directors, tapping her extensive medicinal chemistry and machine‑learning drug‑discovery experience. Leftheris most recently served as Chief Scientific Officer at Vilya, a company focused on oral macrocycle therapeutics, and...
By PharmaTimes
News•Feb 16, 2026
Rebecca Simmons
Qureight announced that Rebecca Simmons has been appointed Chief Operating Officer. The move comes as the company seeks to scale its clinical development platform and broaden its market reach. Simmons joins Qureight after a 15‑year track record in pharmaceutical operations...
By PharmaTimes
News•Feb 9, 2026
Strong Clinical Data for Breye Lead Asset Danegaptide
Breye Therapeutics presented early-phase data on its oral small‑molecule danegaptide for non‑proliferative diabetic retinopathy (NPDR). In a multi‑centre phase 1b study of 24 patients, the drug was well tolerated and achieved plasma concentrations within the target range. More than half of...
By PharmaTimes
News•Feb 5, 2026
Connect More
Veeva Systems’ Aaron Bean outlines five connected engagement models for biopharma, from strategic account management to marketing‑centric approaches, to address mounting access challenges in the UK and Europe. He highlights that HCP accessibility in the UK is only 25% versus...
By PharmaTimes
News•Feb 5, 2026
Patient-Centric Oncology Trials
Pharma companies are redesigning oncology trials to place patients at the center of study design, leveraging real‑world data and digital biomarkers. Adaptive protocols now allow dose adjustments and endpoint modifications based on individual responses. Collaborative platforms connect patients, investigators, and...
By PharmaTimes
News•Feb 4, 2026
Thomas Farrell
NanoSyrinx, a synthetic‑biology firm developing nanosyringe platforms for intracellular delivery, announced Thomas J. Farrell as its new Chief Executive Officer and Director, succeeding founder Joe Healey. Farrell brings more than 25 years of biotherapeutics leadership, having founded two NASDAQ‑listed companies...
By PharmaTimes
News•Jan 29, 2026
ENA Respiratory Begins Dosing in Phase 2 Study of INNA‑051 Nasal Spray
ENA Respiratory has initiated dosing in a Phase 2 clinical trial of its intranasal antiviral, INNA‑051. The study evaluates the spray’s ability to curb viral replication in the upper respiratory tract of adults presenting mild respiratory symptoms. Approximately 200 participants will...
By PharmaTimes
Deals•Jan 27, 2026
Gedeon Richter UK Acquires UK Rights to Cariprazine
Gedeon Richter UK announced that it has taken over the UK rights to the antipsychotic drug cariprazine, expanding its portfolio in the British market. The acquisition is part of the company's strategy to strengthen its presence in mental health treatments....
PharmaTimes